Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

OABI

OmniAb Inc

4.33

Aug 21 • 3:59 PM ET +0.03 (0.70%)

4.35

Aftermarket • 6:10 PM ET +0.02 (0.47%)

Healthcare Biotechnology USA Small NASD

Peers: CAMP HUMA RNA TENX TNXP WHWK MIST UNCY KPTI CNTX

| Held by: IWM VTI IWN IBB VXF SCHA IWC VTWO FESM BUSM

Index	RUT
Market Cap	629.54M
Enterprise Value	596.46M
Income	-44.27M
Sales	38.46M
Book/sh	1.79
Cash/sh	0.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	89
IPO	Sep 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	16.37
P/B	2.42
P/C	12.11
P/FCF	-
EV/EBITDA	-
EV/Sales	15.51
Quick Ratio	4.72
Current Ratio	4.80
Debt/Eq	0.07
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.36
EPS next Y	-0.28
EPS next Q	-0.13
EPS this Y	36.59%
EPS next Y	22.53%
EPS next 5Y	43.10%
EPS past 3/5Y	-29.62% -14.88%
Sales past 3/5Y	-31.89% -14.39%
EPS Y/Y TTM	40.54%
Sales Y/Y TTM	67.01%
EPS Q/Q	69.59%
Sales Q/Q	244.24%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	58.33% 185.85%

Insider Own	18.54%
Insider Trans	-0.12%
Inst Own	49.06%
Inst Trans	-10.05%
ROA	-15.11%
ROE	-16.95%
ROIC	-16.09%
Gross Margin	36.40%
Oper. Margin	-125.96%
Profit Margin	-115.12%
SMA20	47.30%
SMA50	71.69%
SMA200	115.78%
Trades

Shs Outstand	145.39M
Shs Float	118.44M
Short Float	5.06%
Short Ratio	5.99
Short Interest	6.00M
52W High	4.59 -5.66%
52W Low	1.30 233.08%
Volatility	10.07% 8.56%
ATR (14)	0.29
RSI (14)	89.32
Beta	0.55
Rel Volume	1.85
Avg Volume	1.00M
Volume	1,851,882

Perf Week	28.11%
Perf Month	112.25%
Perf Quarter	69.80%
Perf Half Y	154.71%
Perf YTD	134.05%
Perf Year	140.56%
Perf 3Y	-25.34%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.64
Prev Close	4.30
Price	4.33
Change %	0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Aug-17-26 04:47PM	OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook (GuruFocus.com) +13.02%
07:01AM	OmniAb lifts 2026 cash outlook following licensing momentum (InvestorsHub)
06:06AM	OmniAb Raises 2026 Financial Guidance (Business Wire)
06:01AM	OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company (Business Wire)
Aug-07-26 01:06AM	OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... (GuruFocus.com) +37.50%
02:30PM	Loading…
Aug-06-26 02:30PM	VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies (NewMediaWire) +10.34%
Aug-05-26 09:40AM	Earnings To Watch: OmniAb Inc (OABI) Q2 2026 -- GF Value Sees 54% Upside (GuruFocus.com)
Jul-27-26 03:37PM	VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration (NewMediaWire)
Jul-16-26 08:00AM	OmniAb to Report Second Quarter 2026 Financial Results on August 6 (Business Wire)
Jul-13-26 08:00AM	OmniAb Names Amechi Nwachuku Chief Operating Officer (Business Wire) -7.86%
Jul-06-26 12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge)
May-08-26 08:30AM	OmniAb, Inc. Q1 2026 Earnings Call Summary (Moby) +12.93%
May-07-26 04:05PM	OmniAb Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire)
May-06-26 09:33AM	OmniAb Inc (OABI) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-24-26 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire) -6.41%
08:00AM	Loading…
Apr-21-26 08:00AM	OmniAb to Report First Quarter 2026 Financial Results on May 7 (Business Wire)
Mar-05-26 08:30AM	OmniAb, Inc. Q4 2025 Earnings Call Summary (Moby) +10.50%
12:02AM	OmniAb Inc (OABI) Q4 2025 Earnings Call Highlights: Strong Partner Engagement and New ... (GuruFocus.com)
Mar-04-26 07:57PM	OmniAb Q4 Earnings Call Highlights (MarketBeat)
05:55PM	OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (Business Wire)
Mar-03-26 07:20AM	OmniAb Inc (OABI) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-24-26 08:00AM	OmniAb to Participate at the Leerink Partners Global Healthcare Conference (Business Wire)
Feb-19-26 08:00AM	OmniAb to Report Fourth Quarter 2025 Financial Results on March 4 (Business Wire)
Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)

OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

PresidentMr. Matthew W. Foehr

Executive VP of Finance & CFOMr. Kurt A. Gustafson

Chief Legal OfficerMr. Charles S. Berkman J.D.

Executive VP & Chief Operating OfficerMr. Amechi Nwachuku

Senior Vice President of People & TalentMs. Cia McCaffrey

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GUSTAFSON KURT A	Officer	Apr 07 '26	Proposed Sale	1.49	6,913	10,266		Apr 07 08:33 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '26	Option Exercise	0.00	36,459	0	4,439,736	Apr 07 08:26 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '26	Sale	1.49	19,244	28,674	4,420,492	Apr 07 08:26 PM
FOEHR MATTHEW W	Officer	Apr 07 '26	Proposed Sale	1.49	19,244	28,577		Apr 07 08:25 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '26	Option Exercise	0.00	13,542	0	268,396	Apr 07 08:25 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '26	Sale	1.49	6,913	10,300	261,483	Apr 07 08:25 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '26	Option Exercise	0.00	13,542	0	406,242	Apr 07 08:23 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '26	Sale	1.49	7,157	10,664	399,085	Apr 07 08:23 PM
Berkman Charles S	Officer	Apr 07 '26	Proposed Sale	1.49	7,157	10,628		Apr 07 08:12 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '26	Option Exercise	0.00	18,750	0	402,373	Feb 18 06:36 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '26	Sale	1.71	9,673	16,541	392,700	Feb 18 06:36 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 18 '26	Option Exercise	0.00	18,750	0	278,152	Feb 18 06:35 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 18 '26	Sale	1.71	9,301	15,905	268,851	Feb 18 06:35 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '26	Sale	1.71	30,843	52,742	4,403,277	Feb 18 06:34 PM
FOEHR MATTHEW W	President and CEO	Feb 16 '26	Option Exercise	0.00	36,458	0	4,396,541	Feb 17 06:22 PM
FOEHR MATTHEW W	President and CEO	Feb 17 '26	Sale	1.70	20,754	35,282	4,375,787	Feb 17 06:22 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '26	Option Exercise	0.00	13,542	0	266,230	Feb 17 06:20 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 17 '26	Sale	1.70	6,828	11,608	259,402	Feb 17 06:20 PM
Berkman Charles S	Chief Legal Officer	Feb 16 '26	Option Exercise	0.00	13,542	0	390,613	Feb 17 06:18 PM
Berkman Charles S	Chief Legal Officer	Feb 17 '26	Sale	1.70	6,990	11,883	383,623	Feb 17 06:18 PM
FOEHR MATTHEW W	Officer	Feb 17 '26	Proposed Sale	1.70	20,483	34,821		Feb 17 04:33 PM
Berkman Charles S	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:29 PM
GUSTAFSON KURT A	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:27 PM
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM

Open in Screener

LGND

Ligand Pharmaceuticals Inc

286.29

Aug 21 • 3:59 PM ET -1.10 (-0.38%)

286.29

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

LGND Ligand Pharmaceuticals Inc daily Stock Chart

Peers: BMRN IONS AXSM MDGL RYTM VKTX ALNY INCY KROS NBIX

| Held by: IJR VTI IWM VB VBR VXF XSMO SPSM IJT IWO

Index	RUT
Market Cap	5.71B
Enterprise Value	5.48B
Income	197.22M
Sales	290.54M
Book/sh	48.57
Cash/sh	68.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jul 02, 2010
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	47
IPO	Nov 18, 1992

P/E	30.61
Forward P/E	23.63
PEG	1.10
P/S	19.64
P/B	5.89
P/C	4.20
P/FCF	43.40
EV/EBITDA	40.79
EV/Sales	18.87
Quick Ratio	30.96
Current Ratio	31.18
Debt/Eq	1.17
LT Debt/Eq	1.17
Option/Short	Yes / Yes

EPS (ttm)	9.35
EPS next Y	12.11
EPS next Q	2.30
EPS this Y	14.58%
EPS next Y	30.04%
EPS next 5Y	21.39%
EPS past 3/5Y	- -
Sales past 3/5Y	10.96% 7.54%
EPS Y/Y TTM	350.86%
Sales Y/Y TTM	54.89%
EPS Q/Q	813.40%
Sales Q/Q	33.73%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	17.92% 3.90%

Insider Own	2.46%
Insider Trans	-18.60%
Inst Own	114.83%
Inst Trans	2.19%
ROA	12.58%
ROE	21.96%
ROIC	9.40%
Gross Margin	84.28%
Oper. Margin	34.45%
Profit Margin	67.88%
SMA20	-2.28%
SMA50	-2.69%
SMA200	25.43%
Trades

Shs Outstand	19.92M
Shs Float	19.45M
Short Float	11.15%
Short Ratio	6.02
Short Interest	2.17M
52W High	326.63 -12.35%
52W Low	154.91 84.81%
Volatility	3.12% 3.75%
ATR (14)	10.34
RSI (14)	44.83
Beta	1.14
Rel Volume	0.42
Avg Volume	360.36K
Volume	152,535

Perf Week	-2.82%
Perf Month	-5.25%
Perf Quarter	28.85%
Perf Half Y	55.61%
Perf YTD	51.42%
Perf Year	81.99%
Perf 3Y	332.33%
Perf 5Y	326.19%
Perf 10Y	316.67%
Recom	1.00
Target Price	352.40
Prev Close	287.39
Price	286.29
Change %	-0.38%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-26	Initiated	Leerink Partners	Outperform
Jul-21-26	Resumed	Citigroup	Buy	$387
Mar-11-26	Initiated	BofA Securities	Buy	$244
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300

Show Previous Ratings

Aug-06-26 07:18PM	Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ... (GuruFocus.com)
06:40PM	Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary (Moby)
07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press)
07:00AM	Ligand Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-27-26 02:15PM	This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 (Investor's Business Daily)
07:00AM	Loading…
Jul-23-26 07:00AM	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jul-14-26 09:00AM	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets (GlobeNewswire)
Jul-13-26 12:53PM	Agenus shares surge as company secures up to $340M to advance colon cancer trial (Proactive)
08:25AM	Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) (InvestorsHub)
Jun-25-26 04:01PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Jun-23-26 04:00AM	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering (GlobeNewswire) +6.59%
Jun-22-26 07:00AM	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 (GlobeNewswire)
Jun-10-26 07:00AM	Ligand Announces 2026 Investor Day in New York City (GlobeNewswire)
May-27-26 04:01PM	Ligand to Participate in June Investor Conferences (GlobeNewswire)
07:28AM	Loading…
May-07-26 07:28AM	Ligand: Q1 Earnings Snapshot (Associated Press) -9.55%
07:00AM	Ligand Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-27-26 10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
09:10AM	Ligand Pharmaceuticals buying Xoma Royalty for $739 million (Quartz)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Apr-22-26 07:00AM	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +8.85%
Mar-26-26 07:00AM	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (GlobeNewswire)
Mar-12-26 04:25PM	How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma (Investor's Business Daily)
Mar-11-26 01:49PM	Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says (Proactive)
09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
06:11AM	Ligand initiated with a Buy at BofA (TipRanks)
05:14PM	Loading…
Mar-10-26 05:14PM	IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out (Investor's Business Daily)
Mar-06-26 12:47PM	This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% (Investor's Business Daily)
09:12AM	These Are The 5 Best Stocks To Buy Or Watch Now (Investor's Business Daily)
Mar-04-26 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 05:03PM	Ligand Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:10PM	Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highlights: Surpassing Expectations and ... (GuruFocus.com)
07:50AM	Ligand: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
08:44AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

CEO & DirectorMr. Todd C. Davis Ph.D.

Chief Financial OfficerMr. Octavio Espinoza

Chief Legal Officer & SecretaryMr. Andrew T. Reardon J.D.

Senior Vice President of Investments & Business DevelopmentMr. Paul J. Hadden

Executive Director of Investor Relations and Financial Planning & AnalysisMs. Melanie J. Herman CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Option Exercise	56.91	31,641	1,800,574	59,337	Aug 14 05:05 PM
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Sale	292.06	31,641	9,241,229	27,696	Aug 14 05:05 PM
Haas Jason	Director	Aug 12 '26	Option Exercise	51.56	6,138	316,475	11,119	Aug 14 05:04 PM
Haas Jason	Director	Aug 12 '26	Sale	292.81	7,138	2,090,062	3,981	Aug 14 05:04 PM
OCTAVIO ESPINOZA	Officer	Aug 12 '26	Proposed Sale	288.75	31,641	9,136,339		Aug 12 04:33 PM
Jason Haas	Director	Aug 12 '26	Proposed Sale	292.81	7,138	2,090,062		Aug 12 04:23 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Option Exercise	52.27	5,000	261,350	46,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Sale	288.99	5,000	1,444,951	41,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Option Exercise	52.27	5,000	261,350	46,514	Jul 06 05:11 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Sale	313.28	5,000	1,566,377	41,514	Jul 06 05:11 PM
ANDREW REARDON	Officer	Jul 01 '26	Proposed Sale	316.09	10,000	3,160,900		Jul 01 04:57 PM
Sabba Stephen L	Director	Jun 16 '26	Option Exercise	66.13	2,145	141,849	35,774	Jun 18 08:37 AM
Sabba Stephen L	Director	Jun 16 '26	Sale	254.00	2,145	544,830	33,629	Jun 18 08:37 AM
STEPHEN L. SABBA	Director	Jun 16 '26	Proposed Sale	254.00	2,145	544,830		Jun 16 04:30 PM
Haas Jason	Director	Jun 12 '26	Option Exercise	51.56	4,000	206,240	11,442	Jun 15 09:06 PM
Haas Jason	Director	Jun 12 '26	Sale	255.58	6,461	1,651,320	4,981	Jun 15 09:06 PM
Aryeh Jason	Director	Jun 11 '26	Sale	250.00	4,500	1,125,000	102,580	Jun 12 05:27 PM
Aryeh Jason	Director	Jun 10 '26	Sale	250.00	500	125,000	107,080	Jun 12 05:27 PM
LAMATTINA JOHN L	Director	Jun 10 '26	Sale	250.88	4,591	1,151,774	26,969	Jun 12 05:26 PM
JASON HAAS	Director	Jun 12 '26	Proposed Sale	256.00	6,461	1,654,016		Jun 12 04:09 PM
Aryeh Jason	Director	Jun 11 '26	Proposed Sale	249.97	4,500	1,124,880		Jun 11 12:21 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.96	500	124,980		Jun 10 04:45 PM
JOHN L LAMATTINA	Director	Jun 10 '26	Proposed Sale	250.88	4,519	1,133,711		Jun 10 04:07 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.35	5,000	1,246,750		Jun 10 01:41 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Jun 02 06:22 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Sale	227.06	5,000	1,135,316	41,382	Jun 02 06:22 PM
Espinoza Octavio	Chief Financial Officer	May 27 '26	Option Exercise	57.58	1,736	99,966	27,679	May 28 07:43 PM
KOZARICH JOHN W	Director	May 13 '26	Option Exercise	69.51	1,575	109,478	43,361	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Option Exercise	69.51	459	31,905	42,245	May 14 09:08 PM
KOZARICH JOHN W	Director	May 13 '26	Sale	223.50	1,575	352,012	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 01 '26	Sale	231.80	467	108,251	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Sale	224.00	459	102,816	41,786	May 14 09:08 PM
JOHN KOZARICH	Director	May 13 '26	Proposed Sale	223.50	1,575	352,012		May 13 04:09 PM
JOHN KOZARICH	Director	May 12 '26	Proposed Sale	224.00	459	102,816		May 12 05:45 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Option Exercise	52.27	5,000	261,350	46,382	May 04 08:20 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Sale	231.31	5,000	1,156,556	41,382	May 04 08:20 PM
KOZARICH JOHN W	Director	May 01 '26	Proposed Sale	229.87	467	107,349		May 01 04:16 PM
KOZARICH JOHN W	Director	Apr 01 '26	Sale	202.23	467	94,440	42,253	Apr 02 07:43 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Apr 02 06:56 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Sale	201.24	5,000	1,006,224	41,382	Apr 02 06:56 PM
KOZARICH JOHN W	Director	Apr 01 '26	Proposed Sale	203.50	467	95,034		Apr 01 04:10 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Option Exercise	114.15	2,161	246,678	32,885	Mar 31 05:53 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Sale	200.76	2,161	433,842	30,724	Mar 31 05:53 PM
Sabba Stephen L	Director	Mar 23 '26	Sale	207.87	1,000	207,873	32,793	Mar 25 11:13 AM
STEPHEN L. SABBA	Director	Mar 23 '26	Proposed Sale	207.87	1,000	207,873		Mar 23 04:04 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Option Exercise	92.65	2,405	222,823	24,067	Mar 13 07:29 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Sale	225.00	3,057	687,825	21,010	Mar 13 07:29 PM
OCTAVIO ESPINOZA	Officer	Mar 11 '26	Proposed Sale	212.29	3,057	648,971		Mar 11 04:42 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Option Exercise	52.27	5,000	261,350	41,869	Mar 06 06:51 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Sale	206.35	5,000	1,031,770	36,869	Mar 06 06:51 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Option Exercise	63.49	2,073	131,609	35,085	Mar 06 06:49 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Sale	205.83	13,423	2,762,822	21,662	Mar 06 06:49 PM
JOHN L LAMATTINA	Director	Mar 06 '26	Proposed Sale	200.76	2,161	433,842		Mar 06 04:17 PM
Sabba Stephen L	Director	Mar 03 '26	Option Exercise	69.51	2,034	141,383	35,827	Mar 05 11:05 AM
Sabba Stephen L	Director	Mar 03 '26	Sale	201.50	2,034	409,851	33,793	Mar 05 11:05 AM
KOZARICH JOHN W	Director	Mar 02 '26	Sale	200.50	467	93,632	42,720	Mar 04 09:04 PM
ANDREW REARDON	Officer	Mar 04 '26	Proposed Sale	204.24	20,000	4,084,800		Mar 04 04:44 PM
OCTAVIO ESPINOZA	Officer	Mar 04 '26	Proposed Sale	204.24	13,423	2,741,514		Mar 04 04:39 PM
STEPHEN L. SABBA	Director	Mar 03 '26	Proposed Sale	201.50	2,034	409,851		Mar 03 04:27 PM
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM

Open in Screener

TECH

Bio-Techne Corp

72.32

Aug 21 • 3:59 PM ET +0.04 (0.06%)

72.34

Aftermarket • 5:00 PM ET +0.02 (0.03%)

Healthcare Biotechnology USA Large NASD

Peers: RGEN HALO BIO BRKR A MTD WAT TMO DHR IDXX

| Held by: VTI VOO VB RSP IVV VBK SPY FBT IBB XLV

Index	S&P 500
Market Cap	11.32B
Enterprise Value	11.35B
Income	181.84M
Sales	1.22B
Book/sh	13.32
Cash/sh	1.69
Dividend Est.	0.32 (0.44%)
Dividend TTM	0.32 (0.44%)
Dividend Ex-Date	Aug 24, 2026
Dividend Gr. 3/5Y	0.00% 0.00%
Payout	27.59%
Employees	3100
IPO	Feb 09, 1989

P/E	62.44
Forward P/E	30.91
PEG	2.67
P/S	9.32
P/B	5.43
P/C	42.78
P/FCF	42.05
EV/EBITDA	31.06
EV/Sales	9.34
Quick Ratio	3.35
Current Ratio	4.55
Debt/Eq	0.14
LT Debt/Eq	0.13
Option/Short	Yes / Yes

EPS (ttm)	1.16
EPS next Y	2.34
EPS next Q	0.44
EPS this Y	6.50%
EPS next Y	13.85%
EPS next 5Y	11.56%
EPS past 3/5Y	-13.01% 6.01%
Sales past 3/5Y	2.25% 5.47%
EPS Y/Y TTM	152.69%
Sales Y/Y TTM	-0.38%
EPS Q/Q	404.37%
Sales Q/Q	1.33%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	0.12% 2.09%

Insider Own	0.55%
Insider Trans	-0.76%
Inst Own	112.80%
Inst Trans	-3.59%
ROA	7.07%
ROE	9.03%
ROIC	7.63%
Gross Margin	66.19%
Oper. Margin	22.05%
Profit Margin	14.97%
SMA20	0.23%
SMA50	5.01%
SMA200	19.83%
Trades

Shs Outstand	156.57M
Shs Float	155.71M
Short Float	5.96%
Short Ratio	1.93
Short Interest	9.28M
52W High	72.62 -0.41%
52W Low	43.19 67.43%
Volatility	0.42% 0.40%
ATR (14)	0.45
RSI (14)	67.73
Beta	1.28
Rel Volume	0.82
Avg Volume	4.80M
Volume	3,958,011

Perf Week	-0.11%
Perf Month	0.77%
Perf Quarter	52.67%
Perf Half Y	25.73%
Perf YTD	22.97%
Perf Year	33.93%
Perf 3Y	-8.08%
Perf 5Y	-39.66%
Perf 10Y	169.98%
Recom	2.76
Target Price	71.09
Prev Close	72.28
Price	72.32
Change %	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$73
Jun-11-26	Initiated	Piper Sandler	Neutral	$65
May-15-26	Resumed	RBC Capital Mkts	Outperform	$62
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$73
Aug-21-25	Upgrade	Citigroup	Neutral → Buy	$70
Jul-22-25	Resumed	Stephens	Overweight	$65
Jul-09-25	Initiated	TD Cowen	Buy	$65
May-30-25	Initiated	Wells Fargo	Overweight	$59
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform	$75
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral	$88 → $68
May-22-24	Downgrade	Citigroup	Buy → Neutral	$85
Feb-08-24	Initiated	Scotiabank	Sector Outperform	$80
Feb-02-24	Downgrade	Stifel	Buy → Hold	$65
Dec-07-23	Initiated	UBS	Buy	$80
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$90
Dec-14-22	Initiated	Deutsche Bank	Buy	$100
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$81.25 → $100
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$89

Show Previous Ratings

Aug-17-26 10:18PM	Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-13-26 06:30AM	Bio-Techne Corrects Dividend Announcement (PR Newswire)
Aug-12-26 06:30AM	Bio-Techne Releases Fourth Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	Bio-Techne Declares Dividend (PR Newswire)
Jul-08-26 06:30AM	Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio (PR Newswire)
03:27PM	Loading…
Jul-02-26 03:27PM	Are SYNA, IRDM, TECH, PATK Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-01-26 05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-29-26 01:59PM	Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-26-26 10:14AM	Germany's Merck KGaA is buying lab-tools supplier Bio-Techne for $11.3 billion (Quartz)
10:13AM	Merck KGaA to acquire Bio-Techne in $11.3 billion deal (Quartz)
12:01AM	Germanys Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal (The Daily Upside)
Jun-25-26 04:30PM	Bio-Techne Corp. stock outperforms competitors on strong trading day (MarketWatch) +20.08%
01:53PM	Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:09PM	Germany's Merck to Boost Lab-Tools Business With $11 Billion Bio-Techne Deal (The Wall Street Journal)
10:22AM	Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion (Medical Device Network)
07:18AM	Loading…
07:18AM	Germany's Merck Is Buying Bio-Techne for $11.3 Billion (Barrons.com)
06:57AM	Germanys Merck to Acquire Bio-Techne in $11.3 Billion Deal (InvestorsHub)
06:10AM	Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets (PR Newswire)
05:57AM	Qualcomm stock surges on Meta deal, and other early market movers (MarketWatch)
Jun-11-26 09:38AM	SpaceX initiated, Intel upgraded: Wall Street's top analyst calls (The Fly)
Jun-04-26 06:30AM	Bio-Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization (PR Newswire)
May-13-26 04:30PM	Bio-Techne Corp. stock underperforms Wednesday when compared to competitors (MarketWatch) -5.34%
May-07-26 04:30PM	Bio-Techne Corp. stock outperforms competitors on strong trading day (MarketWatch) +7.39% -5.01%
May-06-26 04:57PM	Bio-Techne Corporation Q3 2026 Earnings Call Summary (Moby) -16.36%
06:30AM	Bio-Techne Releases Third Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	Bio-Techne Declares Dividend (PR Newswire)
May-04-26 07:00AM	Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference (PR Newswire)
Apr-16-26 08:00AM	Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity (PR Newswire)
Apr-14-26 07:00AM	Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results (PR Newswire)
Mar-25-26 06:30AM	Bio-Techne Advances Spatial Biology with Modular Expansion of COMET Suite (PR Newswire)
06:18PM	Loading…
Mar-18-26 06:18PM	Evolve Announces March 2026 Distributions for UltraYield ETFs and Certain Evolve Funds (TMX Newsfile)
Mar-06-26 02:01PM	Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know (StockStory)
11:30AM	Why Is Techne (TECH) Down 15.1% Since Last Earnings Report? (Zacks)
Mar-03-26 11:07PM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Feb-24-26 02:28PM	Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections (Insider Monkey) +5.19%
07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Feb-17-26 11:40AM	KMDA or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Feb-16-26 06:30AM	Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories (PR Newswire)
Feb-13-26 08:34PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Feb-11-26 12:04PM	What Are Wall Street Analysts' Target Price for Bio-Techne Stock? (Barchart)
09:00AM	Bio-Techne Announces Changes to its Leadership Team (PR Newswire)
12:36AM	5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call (StockStory)
Feb-06-26 10:22AM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Feb-05-26 12:34AM	TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets (StockStory)
Feb-04-26 04:01PM	Bio-Techne Corp (TECH) Q2 2026 Earnings Call Highlights: Strategic Growth and Margin Expansion ... (GuruFocus.com) +6.25%
11:22AM	Bio-Techne Q2 Earnings Call Highlights (MarketBeat)
10:38AM	Bio-Techne (TECH) Q2 2026 Earnings Call Transcript (Motley Fool)
09:34AM	TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up (Zacks)
09:30AM	Techne (TECH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:37AM	Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales (StockStory)
06:30AM	Bio-Techne Releases Second Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	Bio-Techne Declares Dividend (PR Newswire)
Feb-03-26 08:29AM	MedTech Stocks to Watch for Earnings on Feb. 4: BSX, ALGN & More (Zacks)
Feb-02-26 10:04PM	Bio-Techne (TECH) Reports Earnings Tomorrow: What To Expect (StockStory)
06:30AM	Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative (PR Newswire)
Jan-30-26 11:40AM	CSLLY or TECH: Which Is the Better Value Stock Right Now? (Zacks)
08:44AM	Bio-Techne's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-28-26 06:30AM	Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers (PR Newswire)
Jan-20-26 07:00AM	Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results (PR Newswire)
Jan-12-26 06:49PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Jan-09-26 08:37AM	Here's What to Expect From Bio-Techne's Next Earnings Report (Barchart)
Jan-05-26 11:05PM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory) +5.67%
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
Dec-30-25 10:34PM	Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH) (StockStory)
Dec-23-25 07:00AM	Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 09:17AM	Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? (Zacks)
Dec-16-25 07:40AM	Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector? (Barchart)
Dec-11-25 09:36AM	Here's Why BioTechne (TECH) Traded Lower in Q3 (Insider Monkey)
06:30AM	Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology (PR Newswire)
Dec-09-25 06:30AM	Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis (PR Newswire)
Dec-04-25 10:29AM	Bio-Techne Corporation (TECH): A Bull Case Theory (Insider Monkey)
Nov-25-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Nov-18-25 06:30AM	Bio-Techne Licenses AI-Designed NovoBody Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio (PR Newswire)
Nov-13-25 11:28PM	Bio-Techne Stock: Is Wall Street Bullish or Bearish? (Barchart)
09:01AM	Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector? (Insider Monkey)
Nov-11-25 03:55PM	Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know (StockStory)
Nov-07-25 05:36PM	McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. (Barrons.com)
Nov-06-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Nov-05-25 09:57PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
04:03PM	Bio-Techne Corp (TECH) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
10:52AM	TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Techne (TECH) Q1 Earnings (Zacks)
07:40AM	Techne (TECH) Meets Q1 Earnings Estimates (Zacks)
06:38AM	Bio-Techne (NASDAQ:TECH) Misses Q3 Revenue Estimates, Stock Drops (StockStory)
06:30AM	Bio-Techne Releases First Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Nov-04-25 09:01AM	AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients (PR Newswire)
Nov-03-25 10:17PM	What To Expect From Bio-Techne's (TECH) Q3 Earnings (StockStory)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Sonoma Biotherapeutics (PR Newswire)
Oct-31-25 03:21PM	Why Bio-Techne (TECH) Stock Is Up Today (StockStory)
Oct-30-25 07:27PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 06:30AM	Bio-Techne Launches ProximityScope Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research (PR Newswire)
Oct-23-25 06:56PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
07:54AM	Bio-Techne Q1 Earnings Preview: What's in Store for the Stock? (Zacks)
07:00AM	ScaleReady Announces multiple G-Rex Grants have been awarded to leading investigators at Children's National Hospital (PR Newswire)
Oct-16-25 12:04AM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Oct-15-25 09:00AM	Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents (Business Wire)
07:00AM	Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results (PR Newswire)

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

CEOMr. Kim Kelderman

Executive VP of Finance & CFOMr. James T. Hippel CPA

Senior VPMr. Shane Bohnen

President of Protein Sciences SegmentMr. William A. Geist

VP & CTODr. Gary J. Latham Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelderman Kim	Chief Executive Officer	Aug 15 '26	Option Exercise	0.00	21,470	0	93,583	Aug 18 05:14 PM
Hippel James	CFO	Aug 15 '26	Option Exercise	0.00	9,779	0	174,493	Aug 18 05:13 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Aug 15 '26	Option Exercise	0.00	6,416	0	26,919	Aug 18 05:13 PM
Bohnen Shane	SVP - General Counsel	Aug 15 '26	Option Exercise	0.00	4,350	0	11,703	Aug 18 04:42 PM
Crouse Steven C.	President - Diag & Spatial Bi	Aug 15 '26	Option Exercise	0.00	5,423	0	12,184	Aug 18 04:13 PM
Herr Amy E.	Director	Aug 15 '26	Option Exercise	0.00	589	0	789	Aug 18 04:12 PM
Hippel James	CFO	Jul 29 '26	Option Exercise	47.60	62,068	2,954,437	215,738	Jul 31 05:18 PM
Kelderman Kim	Chief Executive Officer	Jul 28 '26	Option Exercise	47.60	35,000	1,666,000	100,799	Jul 30 04:11 PM
Bohnen Shane	SVP - General Counsel	Jul 23 '26	Option Exercise	47.60	448	21,325	7,697	Jul 27 04:03 PM
Herr Amy E.	Director	May 08 '26	Option Exercise	47.60	6,636	315,874	6,836	May 12 04:04 PM
Herr Amy E.	Director	May 08 '26	Sale	48.28	6,636	320,386	200	May 12 04:04 PM
JOSHUA MOLHO	Director	May 08 '26	Proposed Sale	48.28	6,636	320,417		May 08 04:23 PM
Hippel James	CFO	May 05 '26	Option Exercise	47.60	62,000	2,951,200	210,625	May 07 05:26 PM
Bohnen Shane	SVP - General Counsel	May 05 '26	Option Exercise	47.60	8,400	399,840	14,304	May 07 05:24 PM
Kelderman Kim	Chief Executive Officer	May 05 '26	Option Exercise	47.60	26,692	1,270,539	89,750	May 07 05:22 PM
Kelderman Kim	Chief Executive Officer	Apr 22 '26	Option Exercise	0.00	11,344	0	64,421	Apr 24 06:06 PM
Hippel James	CFO	Apr 22 '26	Option Exercise	0.00	62,000	0	204,722	Apr 24 06:05 PM
Kelderman Kim	Chief Executive Officer	Apr 14 '26	Option Exercise	0.00	36,500	0	85,165	Apr 16 04:19 PM
Bohnen Shane	SVP - General Counsel	Apr 03 '26	Option Exercise	0.00	2,259	0	6,644	Apr 07 04:59 PM
Herr Amy E.	Director	Feb 17 '26	Sale	59.10	1,976	116,791	200	Feb 19 04:57 PM
JOSHUA MOLHO	Director	Feb 17 '26	Proposed Sale	59.10	1,976	116,791		Feb 17 04:19 PM
Herr Amy E.	Director	Feb 03 '26	Option Exercise	0.00	38	0	2,192	Feb 05 06:30 PM
McManus Matthew	President - Diag & Spatial Bio	Feb 01 '26	Option Exercise	0.00	4,621	0	9,356	Feb 03 05:04 PM
Hippel James	CFO	Nov 03 '25	Option Exercise	0.00	24,704	0	154,587	Nov 05 04:46 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Nov 03 '25	Option Exercise	0.00	9,911	0	25,023	Nov 05 04:46 PM
Nusse Roeland	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,599	Aug 27 04:10 PM
Nusse Roeland	Director	Aug 25 '25	Sale	56.36	17,040	960,388	44,559	Aug 27 04:10 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,903	Aug 27 04:09 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Sale	56.21	17,040	957,818	44,863	Aug 27 04:09 PM
ROELAND NUSSE	Director	Aug 25 '25	Proposed Sale	56.36	17,040	960,388		Aug 25 04:05 PM
ROBERT V. BAUMGARTNER4731 BONI	Director	Aug 25 '25	Proposed Sale	56.21	17,040	957,849		Aug 25 04:04 PM

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals Inc

TECH

Bio-Techne Corp

Upgrade your Finviz experience